24 July 2024 - The conversion of this indication from Notice of Compliance to full approval is based on long term outcomes from the GARNET Phase I trial, which demonstrated an objective response rate of 45.5% in patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.

GSK today announced that Health Canada granted full approval for Jemperli (dostarlimab) as a monotherapy for the treatment of adult patients with dMMR/MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen.

Read GSK press release